BALTIMORE, MD, Oct. 15, 2019 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (“The Company”; OTCQB: GCAN), a biopharmaceutical market leader and innovator in the development and commercialization of cannabinoid delivery systems is pleased to update its shareholders that is has successfully developed and tested a transdermal cannabidiol delivery patch. The transdermal patch is a new product that utilizes some of the same proprietary delivery enhancing capabilities that GCAN has been successful in implementing with its eluting transmucosal patch (oral strip). This new milestone culminates close to a year of development and testing using specialized permeability testing equipment.
The transdermal application has broad application, and can be loaded with CBD as well as other active pharmaceutical ingredients (APIs). It can be customized for various transdermal applications to address market opportunities such as wound treatment, treatment of pain and inflammation, as well as delivery of combinations of cannabidiol with other disease modifying pharmaceuticals.
In discussing the new product CEO of Greater Cannabis, Aitan Zacharin, had this to say, “We knew that we wanted to create a leading transdermal CBD product that would build on the years of R&D by our world-class science team. To this end we conducted numerous tests in our lab to determine how the GCAN transdermal patch would compare to a leading transdermal CBD patch product that is currently in market. In addition to quantitative analysis of cannabidiol (CBD) in our transdermal patch using isocratic reversed phase HPLC with UV detection we also looked at the following qualitative tests as critical analyses in determining how our patch performed compared to the leading product:
The GCAN patch showed better skin adhesion, i.e., no lift ups in all four corners versus some wavering and lift ups in some corners of the leading patch. The GCAN patch maintained integrity and uniformity of the patch while the leading patch exhibited some wrinkles and distortions after eight hours of wear, especially in the middle of the patch. The GCAN patch tolerated water exposure very well (no change in skin adhesion), while the leading patch lost quite a bit of adhesion. The GCAN patch showed no irritation at all after peel-off, while the leading patch left some redness upon removal. GCAN’s patch had better quality and performance as evidenced by greater stability and permeability of the API. The leading patch had lower levels of the API that were able to penetrate the dermal skin layers, and the patch exhibited oxidation.
Dr. Hock Tan, chief scientific advisor for Greater Cannabis Company, had this to say about the new product. “Our transdermal technology has been developed for some of the world's largest pharmaceutical companies. We have been able to demonstrate our ability to load high dosages of pharmaceutical ingredients and achieve superior rates of permeability across the skin, all the while maintaining high levels of stability", stated Dr. Hock Tan. "I have personally been involved in the development, testing, and validation of GCAN's cannabinoid transdermal patch, and I believe the results of our technology are stellar. The patch excels in all of the parameters that are critical to a transdermal delivery system as we have been able to show throughout our lab studies", concluded Dr. Tan.
The Company is now pursuing partnerships to commercialize its transdermal patch technology across the vertical including pharmaceutical and consumer products companies. For interest and inquiries about the transdermal technology or any of GCAN’s delivery technology platforms please contact info@gcanrx.com or visit our website gcanrx.com
About The Greater Cannabis Company:
The Greater Cannabis is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.
Disclaimer: GCANRx relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Contact:
The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com
###